February 16th 2024
The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of soft tissue sarcoma.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Olaratumab Receives FDA Approval for Soft Tissue Sarcoma
October 19th 2016The PDGFRα antagonist olaratumab (Lartruvo) has been granted an accelerated approval from the FDA in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS) who are not candidates for radiotherapy or surgery.
Read More
Study Shows Functional Imaging Superior in Assessing Sarcoma Outcomes
October 14th 2016A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses.
Read More
Anthracycline-Based Chemotherapy Produces Significant Survival Benefit in Sarcoma
October 10th 2016A technically negative trial in high-risk adult soft tissue sarcoma nonetheless produced a significant survival benefit for anthracycline-based neoadjuvant chemotherapy, according to a study presented at the 2016 ESMO Congress.
Read More
GIST Experts Moving Toward Personalized Medicine Approach to Treatment
October 5th 2016Lori Rink, PhD, speaks about what oncologists have learned about GIST in the past 3 decades, the important role of imatinib mesylate (Gleevec) in treating the disease, and the personalized treatment approach on the horizon.
Read More
Functional, Anatomic Imaging Compared in Sarcoma Study
September 28th 2016A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses, according to a study published in the <em>Journal of Clinical Oncology</em>.<br />
Read More
Breaking Down Sarcoma, Other Cancers Into Different Types
September 22nd 2016George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses how sarcoma is leading the way in the breakdown of cancers into different types.
Watch
CHMP Recommends Approval of Olaratumab Combo for Soft Tissue Sarcoma
September 22nd 2016The PDGFRα antagonist olaratumab has been recommended approval by The Committee for Medicinal Products for Human Use (CHMP) for use in combination with doxorubicin for patients with advanced soft tissue sarcoma (STS) who are not good candidates for radiotherapy or surgery.
Read More
The Convergence of Targeted Therapies and Immuno-Oncology in Sarcoma
August 9th 2016George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the relevance of sarcoma in the converging worlds of targeted therapies and immuno-oncology.
Watch
Receptor Tyrosine Kinase Inhibitors Show Only Modest Potential in Sarcoma
July 21st 2016Research is making only modest progress in the discovery of receptor tyrosine kinase inhibitors that show benefit in the treatment of sarcomas, Gary K. Schwartz, MD, argued during a presentation at the 2016 ASCO Annual Meeting.
Read More
FDA Grants Olaratumab Priority Review for Soft Tissue Sarcoma
May 5th 2016The FDA has granted an biologics license application for olaratumab a priority review for use in combination with doxorubicin as a treatment of patients with advanced soft tissue sarcoma who are not good candidates for radiotherapy or surgery.
Read More
Novel Molecular Targets for Drug Development in Non-GIST Sarcomas
February 26th 2016In this review, Rodrigo R. Muhoz, MD, William D. Tap, MD, and Sandra P. D'Angelo, MD address the emerging therapeutic strategies aimed at specific molecular targets that could potentially change the approach to patients with soft-tissue sarcomas.
Read More